Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 19/20 | 0.72 |
| ▸ | BCR | P11274 | 16/20 | 0.72 |
| ▸ | KIT | P10721 | 11/20 | 0.72 |
| ▸ | ABL2 | P42684 | 5/20 | 0.72 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.72 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.72 |
| ▸ | SRC | P12931 | 3/20 | 0.72 |
| ▸ | LYN | P07948 | 3/20 | 0.72 |
| ▸ | EGFR | P00533 | 2/20 | 0.72 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.72 |
| ▸ | LCK | P06239 | 2/20 | 0.72 |
| ▸ | FYN | P06241 | 2/20 | 0.72 |
| ▸ | CSF1R | P07333 | 2/20 | 0.72 |
| ▸ | FGR | P09769 | 2/20 | 0.72 |
| ▸ | BRAF | P15056 | 2/20 | 0.72 |
| ▸ | NQO2 | P16083 | 2/20 | 0.72 |
| ▸ | EPHA8 | P29322 | 2/20 | 0.72 |
| ▸ | FRK | P42685 | 2/20 | 0.72 |
| ▸ | BLK | P51451 | 2/20 | 0.72 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL543805 | 0.89 | ABL1 (0.74) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL4282281 | 0.85 | ABL1 (0.78) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL29198404 | 0.85 | ABL1 (0.74) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL3827 | 0.84 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL2236091 | 0.84 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL29355523 | 0.84 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL29351601 | 0.84 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL544504 | 0.84 | ABL1 (0.58) | ABL1BCRKITPDGFRAPDGFRB | |
| Imatinib SCHEMBL529425 | 0.83 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL16431247 | 0.83 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718676-B2 | E.g., Methyl 4-{[4-Methyl-3-(4-pyridin-3-yl-oxazol-2-ylamino)-phenylamino]-methyl}-benzoate; stem cell factor, bcr-abl, fibroblastic growth factor receptor-3 and Flt-3 inhibitors; treating rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, transplant rejection | AB SCIENCE (FR) | 2010-05-18 | — | — | US | claimed |
| EP-1684750-B1 | 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2010-04-28 | — | — | EP | claimed |
| US-20070142390-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE | 2007-06-21 | — | — | US | claimed |
| EP-1684750-A2 | 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS | AB Science (FR) | 2006-08-02 | — | — | EP | claimed |
| WO-2005040139-A2 | 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2005-05-06 | — | — | WO | claimed |
| US-8110591-B2 | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE (FR) | 2012-02-07 | — | — | US | disclosed |
| US-8110591-B2 | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE (FR) | 2012-02-07 | — | — | US | disclosed |
| US-8110591-B2 | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE (FR) | 2012-02-07 | — | — | US | disclosed |
| US-7718676-B2 | E.g., Methyl 4-{[4-Methyl-3-(4-pyridin-3-yl-oxazol-2-ylamino)-phenylamino]-methyl}-benzoate; stem cell factor, bcr-abl, fibroblastic growth factor receptor-3 and Flt-3 inhibitors; treating rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, transplant rejection | AB SCIENCE (FR) | 2010-05-18 | — | — | US | disclosed |
| US-7718676-B2 | E.g., Methyl 4-{[4-Methyl-3-(4-pyridin-3-yl-oxazol-2-ylamino)-phenylamino]-methyl}-benzoate; stem cell factor, bcr-abl, fibroblastic growth factor receptor-3 and Flt-3 inhibitors; treating rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, transplant rejection | AB SCIENCE (FR) | 2010-05-18 | — | — | US | disclosed |
| US-7718676-B2 | E.g., Methyl 4-{[4-Methyl-3-(4-pyridin-3-yl-oxazol-2-ylamino)-phenylamino]-methyl}-benzoate; stem cell factor, bcr-abl, fibroblastic growth factor receptor-3 and Flt-3 inhibitors; treating rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, transplant rejection | AB SCIENCE (FR) | 2010-05-18 | — | — | US | disclosed |
| US-20100113471-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE | 2010-05-06 | — | — | US | disclosed |
| US-20070225293-A1 | Use of C-Kit Inhibitors for Treating Fibrosis | AB SCIENCE | 2007-09-27 | — | — | US | disclosed |
| US-20070225293-A1 | Use of C-Kit Inhibitors for Treating Fibrosis | AB SCIENCE | 2007-09-27 | — | — | US | disclosed |
| US-20070225293-A1 | Use of C-Kit Inhibitors for Treating Fibrosis | AB SCIENCE | 2007-09-27 | — | — | US | disclosed |
| US-20070142390-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE | 2007-06-21 | — | — | US | disclosed |
| US-20070142390-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE | 2007-06-21 | — | — | US | disclosed |
| US-20070142390-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE | 2007-06-21 | — | — | US | disclosed |
| EP-1684750-A2 | 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS | AB Science (FR) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005040139-A2 | 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225293-A1 | Use of C-Kit Inhibitors for Treating Fibrosis | KIT, CPA3, CMA1 | ABL1 419/4885BCR 2636/4885KIT 1/4885 |
| US-20070142390-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | FGFR3, ABL1, FLT3 | ABL1 2/4885BCR 8/4885KIT 9/4885 |
| US-20100113471-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | FGFR3, FLT3, ABL1 | ABL1 3/4885BCR 8/4885KIT 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.